Dietary advice for people with schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Pearsall, Robert ^a   Thyarappa Praveen, Kudlar ^b   Pelosi, Anthony ^c   Geddes, John ^d  

^a MONKLANDS HOSPITAL   (United Kingdom)

^b SOUTH WEST YORKSHIRE PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^c ST JOHN'S HOSPITAL   (United Kingdom)

^d WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BODY MASS; COGNITION; DIET THERAPY; DIETARY INTAKE; FOLLOW UP; HUMAN; MENTAL HEALTH; NEGATIVE SYNDROME; NUTRITIONAL STATUS; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; WAIST HIP RATIO; WEIGHT CHANGE; COUNSELING; DIET; LIFESTYLE;

COUNSELING; DIET; HUMANS; LIFE STYLE; SCHIZOPHRENIA;

EID: 84961903983     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009547.pub2     Document Type: Review

References (105)

1. 09723 Nursing intervention of antipsychotic-induced weight gain. Shandong Archives of Psychiatry 2005;18(4):272.
2. 17224 A study on the nursing intervention with the olanzapine induced weight-gain. Journal of Nursing Science 2005;20(11):42-3.
3. Baptiste JM, Liskov E, Chakunta UR, Hassan AQ, Brownell K, Wexler BE. Pilot study to investigate the effects of a weight management program in conjunction with food provision on cardiovascular and endocrine risk factors in patients with schizophrenia or schizoaffective disorder who are treated with antipsychotic medications. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006.
4. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 2005;66(2):205-12.
5. Brown C, Goetz J, Hamera E. Weight loss intervention for people with serious mental illness: a randomized controlled trial of the renew program. Psychiatric Services 2011;62(7):800-2.
6. Castrogiovanni S, Simoncini M, Iovieno N, Cecconi D, Dell'Agnello G, Donda P, et al. Efficacy of a psychoeducational program for weight loss in patients who have experienced weight gain during treatment with olanzapine. European Neuropsychopharmacology 2006;16:S441.
7. Cordes J. Efficacy of the BELA weight management programme to prevent increase of weight in schizophrenic patients treated with olanzapine (BELA = movement - nutrition - learning - accepting). http://www.controlled-trials.com 2008.
8. Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, et al. A behavioral weight-loss intervention in persons with serious mental illness. New England Jourrnal of Medicine 2013;368(17):1594-1602.
9. Eli Lilly. Assessment of safety and efficacy of therapy for the prevention of weight gain associated with olanzapine. Eli Lilly and Company Clinical Trial Registry 2006.
10. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Australian and New Zealand Journal of Psychiatry 2005;39(6):479-86.
11. Fan A. Nursing intervention on the weight of the obese patients olanzapine. Journal of Nursing Science 2005;20(11):42-3.
12. Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. Journal of Clinical Psychiatry 2009;70(1):58-62.
13. Ganguli R, Brar JS. Prevention of weight gain, by behavioral interventions, in patients starting novel antipsychotics. Schizophrenia Bulletin 2005;31:561-2.
14. Ganguli R, Brar JS. Weight maintenance by booster behavioral sessions in schizophrenia subjects who lost weight in a behavioral program. Schizophrenia Bulletin 2009;35:41.
15. Ganguli R, Brar JS. Weight reduction in schizophrenia, by lifestyle change: a randomized clinical trial. Canadian Journal of Diabetes 2011;2:153.
16. Goetz J, Brown C, Hamera E. Preliminary 1-year results of the renew program for weight loss. Schizophrenia Bulletin 2011;1:304.
17. Iglesias-Garcia C, Toimil-Iglesias A, Alonso-Villa MJ. Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia. Journal of Psychiatric Mental Health Nursing 2010;17(9):849-51.
18. Kelly C. A randomised control trial. National Research Register 2002; Vol. 3.
19. Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S, Pomini V, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophria Research 2007;91(1-3):169-77.
20. Klaras ES, Kovac J, Plommon M, Nilsson PM, Ostapowicz A. The effect of lifestyle intervention to prevent weight gain during treatment with atypical antipsychotic drugs - a randomized study. European Neuropsychopharmacology 2006;16:S413.
21. Kwon JS, Choi J-S, Bahk W-M, Kim CY, Kim CH, Shin YC, et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. Journal of Clinical Psychiatry 2006;67(4):547-53.
22. McCreadie RG, Kelly C, Connolly M, Williams S, Baxter G, Lean M, et al. Dietary improvement in people with schizophrenia: a randomised controlled trial. British Journal of Psychiatry 2005;187(4):346-51.
23. McDougall S. The effect of nutritional education on the shopping and eating habits of a small group of chronic schizophrenic patients living in the community. British Journal of Occupational Therapy 1992;55(2):62-8.
24. NCT00158366 A clinical trial of weight reduction in schizophrenia. http://www.clinicaltrials.gov. 2005.
25. NCT00169702 The effect of a weight management program to prevent weight gain and metabolic abnormalities during treatment with the atypical neuroleptic olanzapine: a randomised study. http://www.clinicaltrials.gov. 2005.
26. NCT00177905 A clinical trial of weight reduction in schizophrenia. http://www.clinicaltrials.gov. 2005.
27. NCT00191828 A prospective/parallel study on induced weight gain during atypical antipsychotic treatment and its management with psychoeducational programme. http://www.clinicaltrials.gov. 2005.
28. NCT00485823 The assessment of a weight management program for treatment-emergent weight gain in patients with schizophrenia, schizophreniform disorder, and schizoaffective disorder during olanzapine therapy. http://www.clinicaltrials.gov. 2007.
29. NCT00572247 The psychiatric rehabilitation approach to weight loss. http://www.clinicaltrials.gov 2007.
30. NCT00790517 Reducing weight and diabetes risk in an underserved population (STRIDE). http://www.clinicaltrials.gov. Vol. 2008.
31. NCT00990925 Lifestyle modification for weightloss in schizophrenia. http://www.clinicaltrials.gov. 2009.
32. NCT01052714 Healthy lifestyles for mentally ill people who have experienced weight gain from their antipsychotic medications. http://www.clinicaltrials.gov. 2010.
33. NCT01075295 Prevention of weight gain in early schizophrenia and schizoaffective disorder. http://www.clinicaltrials.gov. 2010.
34. NCT01272752 Anti-psychotic medication (new use) weight loss study. http://ClinicalTrials.gov/show/NCT01272752. 2011.
35. NCT01272765 Anti-psychotic medication (stable dose) weight loss study. http://ClinicalTrials.gov/show/NCT01272765. 2011.
36. NCT01324973 Web-based weight management for individuals with mental illness. http://ClinicalTrials.gov/show/NCT01324973. 2011.
37. NCT01368406 Lifestyle intervention for weight gain management for patients with schizophrenia. http://ClinicalTrials.gov/show/NCT01368406. 2011.
38. NCT01491490 Treatment on iatrogenic weight gain and dyslipidaemia associated with olanzapine. http://ClinicalTrials.gov/show/NCT01491490. 2011.
39. Pfizer A phase II, open-label, randomized, 6-way crossover study to estimate the impact of total calories and fat content on the steady-state serum concentrations of ziprasidone in patients receiving oral ziprasidone 80 mg bid. http://www.clinicalstudyresults.org/ 2007.
40. Rossotto E, Wirshing D, Wirshing W, Boyd J, Liberman R, Marder S. Reducing rehospitalization rates for patients with schizophrenia: the community re-entry supplemental intervention. Schizophrenia Research 2003;60(1):328.
41. Rotatori AF, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self-control program. Psychological Reports 1980;46(2):483-6.
42. Scocco P, Longo P, Caon F. Weight change in treatment with olanzapine and a psychoeducational approach. Eating Behaviours 2006;7:115-24.
43. Wang BH//Du GP. Behavioural intervention for antipsychotic caused weight gain. Medical Journal of Chinese People's Health 2008;20(18):2117-8.
44. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research 2006;83(1):95-101.
45. Zhang C, Fan M, Cao H. The effect of the psychological intervention on losing weight with antipsychotic. Chinese Journal of Health Psychology 2008;16(2):126-8.
46. NCT02130596 An Acceptance-Based Behavioral Intervention vs. Nutritional Counselling for Weight Loss in Psychotic Illness. https://www.clinicaltrials.gov/ct/show/NCT02130596 [Date Accessed: 24 February 2016].
47. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
48. Ammerman AS, Lindquist CH, Lohr KN, Hersey J. The efficacy of behavioural interventions to modify dietary fat, fruit and vegetable intake: a review of the evidence. Preventative Medicine 2002;35:25-41.
49. Bland JM, Kerry SM. Statistical notes. Trials randomised in clusters. BMJ 1997;315(7108):600.
50. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
51. Brown S, Birtwistle J. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 1999;29(3):697-701.
52. Brunner EJ, Rees K, Ward K, Burke M, Thorogood M. Dietary advice for reducing cardiovascular risk. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002128.pub3]
53. Carpenter WT, Buchannan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
54. Chafetz L, White M, Collins-Bride G, Cooper B, Nickens J. Clinical trial of wellness training: health promotion for severely mentally ill adults. Journal of Nervous and Mental Disease 2008;196(6):475.
55. Daumit GL, Goldberg RW, Anthony C, Dickerson F. Physical activity patterns in adults with severe mental illness. Journal of Nervous and Mental Disease 2005;193:641-6.
56. De Hert MA, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research 2006;83(1):87-93.
57. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
58. Department of Health. Choosing a better diet. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4105356 (accessed 5 September 2011).
59. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behaviour. Journal of General Internal Medicine 1992;7(6):623-9.
60. Donner A, Klar N. Issues in the meta-analysis of cluster randomised trials. Statistics in Medicine 2002;21(19):2971-80.
61. Egger M, Davey SG, Scheider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
62. Elbourne D, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
63. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Australian and New Zealand Journal of Psychiatry 2005;39(6):479-86.
64. Filik R, Sipos A, Kehoe PG, Burns T, Cooper SJ. The cardiovascular and respiratory health of people with schizophrenia. Acta Psychiatrica Scandinavica 2006;113:298-305.
65. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
66. Goff DC, Sullivan LM, McEvoy JP. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research 2005;80:45-53.
67. Green A, Patel J, Goisman R. Weight gain from novel antipsychotics drugs: need for action. General Hospital Psychiatry 2000;22:224-35.
68. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83.
69. Heimberg C, Gallacher F, Gur RC, Gur RE. Diet and gender moderate clozapine-related weight gain. Human Psychopharmacology 1995;10:367.
70. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60.
71. Higgins JPT, Deeks JJ (editors). In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
72. Hooper L, Griffiths E, Abrahams C, Alexander W, Atkins S, Atkinson G. Dietetic guidelines: diet in secondary prevention of cardiovascular disease. Journal of Human Nutrition and Dietetics 2003;17:337-49.
73. Huxley RR, Lean M, Crozier A, John JH, Neil HAW. Effect of dietary advice to increase fruit and vegetable consumption on plasma flavonol concentrations: results from a randomized controlled intervention trial. Journal of Epidemiology and Community Health 2004;58:288-9.
74. Irving CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD001257.pub2]
75. Jenkins DJA, Kendall CWC, McKeown-Essen G, Josse RG, Silverberg J. Effect of a low-glycaemic index or a high-cereal fibre diet on type 2 diabetes. Journal of American Medical Association 2008;300(23):2742-53.
76. Joshipura KJ, Hu FB, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, et al. The effect of fruit and vegetable intake on risk for coronary heart disease. Annals of Internal Medicine 2001;134:1106-14.
77. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
78. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophrenia Research 2011;131:101-4.
79. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]
80. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
81. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
82. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica 2007;116:317-33.
83. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials. American Journal of Psychiatry 2000;176:249-52.
84. McCreadie RG, Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. British Journal of Psychiatry 2003;183:534-9.
85. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry 1996;37:68-73.
86. Ness AR, Hughes J, Elwood PC, Whitley E, Smith GD, Burr ML. The long-term effect of dietary advice in men with coronary disease: follow-up of the diet and reinfarction trial (DART). European Journal of Clinical Nutrition 2002;56:512-8.
87. Newcomer JW, Haupt DW. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry 2002;59:337-45.
88. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
89. Oxman AD, Guyatt GH. A consumer's guide to subgroup analysis. Annals of Internal Medicine 1992;116(1):78-84.
90. Paton C, Esop R, Young C. Obesity, dyslipidaemias, and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatrica Scandinavica 2004;110:299-305.
91. Pearsall R, Hughes S, Geddes J, Pelosi A. Understanding the problems developing a healthy living programme in patients with serious mental illness: a qualitative study. Biomedical Central Psychiatry 2014;1:38-40.
92. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 2010;123(2-3):225-33.
93. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time. Archives of General Psychiatry 2007;64(10):1123-31.
94. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
95. The Scottish Goverment. Scottish Health Survey. Edinburgh 2010 (www. scotland.gov.uk/publications).
96. Srassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: A preliminary study. Schizophrenia Research 2003;29(2):393-7.
97. STATA Corporation. STATA. Version 8. STATA Corporation, 2005.
98. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
99. Susce MT, Villanueva N, Diaz FJ, De Leon J. Obesity and associated complications in patients with severe mental illness: a cross-sectional survey. Journal of Clinical Psychiatry 2005;66:167-73.
100. The Schizophrenia Commission. The abandoned illness: a report from the Schizophrenia Commission 2012; Vol. London, issue Rethink Mental Illness:1-88.
101. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organization-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):88-92.
102. Ussher M, Doshi R, Sampuran A, West R. Cardiovascular risk factors in patients with schizophrenia receiving continuous medical care. Community Mental Health Journal 2011;47(6):688-93.
103. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatric Services 2003 August 1;54(8):1155-7.
104. Weinemann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research 2009;113(1):1-11.
105. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.